Genentech Inc., of South San Francisco, a unit of the Roche Group, and OSI Pharmaceuticals, a wholly owned subsidiary of Deerfield, Ill.-based Astellas U.S. Holding Inc., said an independent data monitoring committee recommended that the Phase III EURTAC (European Randomized Trial of Tarceva vs. Chemotherapy) in non-small-cell lung cancer (NSCLC) be stopped early because it met its primary endpoint.